Cargando…
Circulating active von Willebrand factor and immunoglobulin A nephropathy outcomes
Autores principales: | Gutiérrez, Eduardo, Eduardo, Hernández, Morales, Enrique, Praga, Manuel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8612135/ https://www.ncbi.nlm.nih.gov/pubmed/34840735 http://dx.doi.org/10.1093/ckj/sfaa140 |
Ejemplares similares
-
Neutrophil extracellular traps and von Willebrand factor are allies that negatively influence COVID‐19 outcomes
por: Fernández‐Pérez, María P., et al.
Publicado: (2021) -
Role of lupus anticoagulant and von Willebrand factor in chronic reactive endotheliitis in COVID-19
por: López Reboiro, Manuel Lorenzo, et al.
Publicado: (2021) -
Reply to “Comment on: A comparative study in type 2 von Willebrand disease patients using four different platelet-dependent von Willebrand factor assays”
por: Colpani, Paola, et al.
Publicado: (2023) -
Letter in response to Colpani et al “A comparative study in type 2 von Willebrand disease patients using four different platelet-dependent von Willebrand factor assays”
por: Favaloro, Emmanuel J.
Publicado: (2023) -
Efficacy and safety evaluation of Fanhdi(®), a plasma‐derived factor VIII/ von Willebrand factor concentrate, in Von Willebrand's disease patients undergoing surgery or invasive procedures: A prospective clinical study
por: Jimenez‐Yuste, Victor, et al.
Publicado: (2021)